These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 3091708

  • 21. Safety and immunogenicity of Klebsiella pneumoniae K1 capsular polysaccharide vaccine in humans.
    Cryz SJ, Fürer E, Germanier R.
    J Infect Dis; 1985 Apr; 151(4):665-71. PubMed ID: 3882856
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Vaccine potential of Pseudomonas aeruginosa O-polysaccharide-toxin A conjugates.
    Cryz SJ, Lang AB, Sadoff JC, Germanier R, Fürer E.
    Infect Immun; 1987 Jul; 55(7):1547-51. PubMed ID: 3110065
    [Abstract] [Full Text] [Related]

  • 24. Synthesis and characterization of a polyvalent Escherichia coli O-polysaccharide-toxin A conjugate vaccine.
    Cryz SJ, Que JO, Cross AS, Fürer E.
    Vaccine; 1995 Apr; 13(5):449-53. PubMed ID: 7639013
    [Abstract] [Full Text] [Related]

  • 25. Use of Pseudomonas aeruginosa toxin A in the construction of conjugate vaccines and immunotoxins.
    Cryz SJ, Fürer E, Sadoff JC, Germanier R, Pastan I, Willingham MC, FitzGerald DJ.
    Rev Infect Dis; 1987 Apr; 9 Suppl 5():S644-9. PubMed ID: 3120274
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. [Results of using polyvalent Pseudomonas aeruginosa vaccine in children with burns by various medical centers].
    Bbukowska D, Serafińska D, Rudowski W, Hoffman S, Olański W, Gardzińska E, Popiel D, Jedrzejczak G, Czarnecka I.
    Pol Tyg Lek; 1987 Apr; 44(43-45):924-7. PubMed ID: 2518666
    [Abstract] [Full Text] [Related]

  • 28. Effect of high-affinity anti-Pseudomonas aeruginosa lipopolysaccharide antibodies induced by immunization on the rate of Pseudomonas aeruginosa infection in patients with cystic fibrosis.
    Lang AB, Schaad UB, Rüdeberg A, Wedgwood J, Que JU, Fürer E, Cryz SJ.
    J Pediatr; 1995 Nov; 127(5):711-7. PubMed ID: 7472821
    [Abstract] [Full Text] [Related]

  • 29. Pseudomonas aeruginosa antigens as potential vaccines.
    Stanislavsky ES, Lam JS.
    FEMS Microbiol Rev; 1997 Nov; 21(3):243-77. PubMed ID: 9451816
    [Abstract] [Full Text] [Related]

  • 30. Phase 1 and phase 2 studies of Salmonella enterica serovar paratyphi A O-specific polysaccharide-tetanus toxoid conjugates in adults, teenagers, and 2- to 4-year-old children in Vietnam.
    Konadu EY, Lin FY, Hó VA, Thuy NT, Van Bay P, Thanh TC, Khiem HB, Trach DD, Karpas AB, Li J, Bryla DA, Robbins JB, Szu SC.
    Infect Immun; 2000 Mar; 68(3):1529-34. PubMed ID: 10678970
    [Abstract] [Full Text] [Related]

  • 31. Safety and immunogenicity of high molecular weight polysaccharide vaccine from immunotype 1 Pseudomonas aeruginosa.
    Pier GB.
    J Clin Invest; 1982 Feb; 69(2):303-8. PubMed ID: 6799548
    [Abstract] [Full Text] [Related]

  • 32. Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection.
    Preston MJ, Gerçeker AA, Koles NL, Pollack M, Pier GB.
    Invest Ophthalmol Vis Sci; 1997 Jun; 38(7):1418-25. PubMed ID: 9191605
    [Abstract] [Full Text] [Related]

  • 33. Protective efficacy of Pseudomonas aeruginosa type-A flagellin in the murine burn wound model of infection.
    Faezi S, Safarloo M, Amirmozafari N, Nikokar I, Siadat SD, Holder IA, Mahdavi M.
    APMIS; 2014 Feb; 122(2):115-27. PubMed ID: 23758581
    [Abstract] [Full Text] [Related]

  • 34. Qualitative analysis of antibody binding. An in vitro assay for the evaluation and development of vaccines.
    Bruderer U, Fürer E, Cryz SJ, Lang AB.
    J Immunol Methods; 1990 Oct 19; 133(2):263-8. PubMed ID: 2121830
    [Abstract] [Full Text] [Related]

  • 35. Systematic generation of antigen specific human monoclonal antibodies with therapeutical activities using active immunization.
    Lang AB, Fürer E, Senyk G, Larrick JW, Cryz SJ.
    Hum Antibodies Hybridomas; 1990 Oct 19; 1(2):96-103. PubMed ID: 2129420
    [Abstract] [Full Text] [Related]

  • 36. Human monoclonal antibodies to Pseudomonas aeruginosa type-specific lipopolysaccharides, toxin A and Klebsiella capsular polysaccharides.
    Lang AB, Fürer E, Schürch U, Cross AS, Larrick JW, Cryz SJ.
    Dev Biol Stand; 1990 Oct 19; 71():121-6. PubMed ID: 1698165
    [Abstract] [Full Text] [Related]

  • 37. Design and immunological properties of Helicobacter pylori glycoconjugates based on a truncated lipopolysaccharide lacking Lewis antigen and comprising an α-1,6-glucan chain.
    Altman E, Chandan V, Harrison BA, Veloso-Pita R, Li J, KuoLee R, Chen W, Vérez-Bencomo V, Regional Helicobacter pylori Study Group.
    Vaccine; 2012 Nov 26; 30(50):7332-41. PubMed ID: 22534169
    [Abstract] [Full Text] [Related]

  • 38. Opsonic and protective activity of five human IgM monoclonal antibodies reactive with lipopolysaccharide antigen of Pseudomonas aeruginosa.
    Collins MS, Ladehoff DK, Mehton NS, Noonan JS.
    FEMS Microbiol Immunol; 1990 Dec 26; 2(5-6):263-8. PubMed ID: 2127368
    [Abstract] [Full Text] [Related]

  • 39. Multi-valent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal pseudomonas sepsis caused by multiple serotypes.
    Lai Z, Kimmel R, Petersen S, Thomas S, Pier G, Bezabeh B, Luo R, Schreiber JR.
    Vaccine; 2005 May 09; 23(25):3264-71. PubMed ID: 15837231
    [Abstract] [Full Text] [Related]

  • 40. Motility, virulence, and protection with a flagella vaccine against Pseudomonas aeruginosa infection.
    Montie TC, Drake D, Sellin H, Slater O, Edmonds S.
    Antibiot Chemother (1971); 1987 May 09; 39():233-48. PubMed ID: 3118785
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.